Analysts Set Biogen Inc. (NASDAQ:BIIB) PT at $211.96

Biogen Inc. (NASDAQ:BIIB) has been assigned an average rating of “Hold” from the thirty research firms that are currently covering the firm, MarketBeat.com reports. Seventeen research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $213.33.

Several research analysts recently commented on the company. HC Wainwright reduced their price objective on Biogen from $300.00 to $241.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Bank Of America (Bofa) cut their target price on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 11th. Wells Fargo & Company lowered their price target on Biogen from $165.00 to $140.00 and set an “equal weight” rating for the company in a research report on Thursday, February 13th. Scotiabank cut their price objective on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a research report on Thursday, February 13th. Finally, William Blair restated an “outperform” rating on shares of Biogen in a report on Monday, January 13th.

Biogen Stock Up 2.6 %

Shares of BIIB opened at $140.64 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The stock has a market capitalization of $20.59 billion, a price-to-earnings ratio of 12.57, a price-to-earnings-growth ratio of 1.47 and a beta of -0.08. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00. The business’s 50 day simple moving average is $145.16 and its 200-day simple moving average is $170.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. As a group, equities analysts expect that Biogen will post 15.83 earnings per share for the current fiscal year.

Institutional Trading of Biogen

A number of hedge funds have recently bought and sold shares of BIIB. Lee Danner & Bass Inc. bought a new position in shares of Biogen in the 4th quarter worth $25,000. Larson Financial Group LLC raised its holdings in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 141 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Biogen during the third quarter valued at about $33,000. Colonial Trust Co SC boosted its holdings in shares of Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 186 shares in the last quarter. Finally, SRS Capital Advisors Inc. purchased a new position in shares of Biogen in the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.